title: Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
abstract: The anti-tumor necrosis factor (TNF)-α agents represent the second generation of psoriasis therapy. Research has produced a third generation of biologic treatments, some of which offer greater efficacy than the TNF-α inhibitors. This article reviews the data documenting the efficacy and safety of three types of biologics.
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D053762:Interleukin-12 Subunit p40 / Q000037:antagonists & inhibitors*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D053762:Interleukin-12 Subunit p40; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha; C000588857:guselkumab; C544528:briakinumab; D000069549:Ustekinumab